文献速递免疫规划传染病防控与疫情报告

辉瑞-BioNTech疫苗接种在医护人员队列中的安全性:未感染与既往感染SARS-CoV-2者的差异

Safety of Pfizer-BioNTech vaccine in a cohort of healthcare providers: Differences between naïve and previously infected by SARS-CoV-2.
PubMed 文献 · Vaccine · 2022-05-12

该回顾性队列研究纳入医护人员,记录辉瑞疫苗接种后不良事件(AE),比较既往SARS-CoV-2感染与未感染者。既往感染与第一剂后更多AE相关(p<0.001),但与第二剂后无关(p=0.476);不同AE绝对数增加的RR第一剂为1.18(95%CI [1.05, 1.33]),第二剂为1.05(95%CI [0.96, 1.14])。结论为有既往COVID-19史者AE发生率更高。

要点

  • 既往SARS-CoV-2感染与第一剂辉瑞疫苗接种后更多不良事件相关(p<0.001)。
  • 既往感染与第二剂后不良事件无显著关联(p=0.476)。
  • 关节痛、乏力、发热、寒战、头痛和肌痛与既往COVID感染统计相关(p≤0.001)。

核心结论

  • 有既往COVID-19感染史的个体不良事件发生率更高。

研究设计与样本

  • 回顾性队列研究,人群为医护人员,记录辉瑞疫苗第一剂和第二剂相关不良事件,比较既往SARS-CoV-2感染与未感染者,计算相对风险(RR)及95%置信区间。

主要发现

  • 既往感染与第一剂后更多不良事件相关(p<0.001),但与第二剂后无关(p=0.476),且不良事件发生率更高(p<0.001)。
  • 与既往COVID感染统计相关的不良事件包括关节痛、乏力、发热、寒战、头痛和肌痛(p≤0.001)。
  • 不同不良事件绝对数增加的RR:第一剂后为1.18(95%CI [1.05, 1.33]),第二剂后为1.05(95%CI [0.96, 1.14])。
  • 既往感染与疫苗接种间隔最长为306天。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: The Spanish Society of Immunology recently warned that a history of past COVID-19 could result in a higher incidence of adverse events (AEs) related to vaccination. We set out to analyze whether there were any differences in AEs between healthcare workers vaccinated for COVID-19 (either after the first or second dose) who had had a prior diagnosis SARS-CoV-2 infection at any time compared to those who had not had COVID-19 before vaccination. METHODS: This was a retrospective cohort study in a population of healthcare workers. AEs related to the first and second doses of the Pfizer vaccine were recorded. We compared the incidence of AEs and compared individuals with 0-3 different AEs to those with 4 or more AEs. The relative risks (RR) and their 95% confidence intervals were calculated. RESULTS: Past infection was associated with having more AEs after the first dose (p < 0.001), but not the second one (p = 0.476), as well as a higher incidence of AEs (p < 0.001). Common AEs that were statistically associated with past COVID infection included arthralgia, asthenia, fever, chills, headache, and myalgia (p ≤ 0.001). The RR for having an increased absolute number of different AEs was 1.18 (95 %CI [1.05, 1.33]) after the first dose and 1.05 (95 %CI [0.96, 1.14]) after the second dose. The maximum number of days between past infection and vaccination was 306. CONCLUSIONS: Our results showed that the incidence of AEs was higher in individuals with a history of prior COVID-19 infection.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Chong-Valbuena A, De-Jesús-María I, Agurto-Ramírez A, et al. Safety of Pfizer-BioNTech vaccine in a cohort of healthcare providers: Differences between naïve and previously infected by SARS-CoV-2. Vaccine. 2022. PMID: 35643563. doi:10.1016/j.vaccine.2022.05.015

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。